



Kennedy Krieger Institute

Michael V. Johnston, M.D.
Executive Vice President
Chief Medical Officer
Blum/Moser Chair for
Pediatric Neurology

Professor of Neurology, Pediatrics
and PM&R
Johns Hopkins University
School of Medicine

February 21, 2013

Dear Editor,

Please find enclosed the duplicate manuscript containing an electronic copy of the full-text manuscript in Word format (TreatmentofAutism_wjcp_2013_00742189_review.doc).

Title: Potential for Treatment of Severe Autism in Tuberous Sclerosis Complex

Authors: Tanjala T. Gipson, Gwendolyn Gerner, Mary Ann Wilson, Mary E. Blue, Michael V. Johnston

We reviewed the literature regarding autism in TSC to identify opportunities and potential barriers to treatment of children with severe autism. Our review identified available mechanism-based treatments with potential for impact in this population; however, these children are at risk for exclusion from clinical trials. Clearly defining the population and identifying reliable outcome measures were identified as a need for clinical trial design in this population.

The content of the manuscript is original and it has not been published or accepted for publication, either in whole or in part, in any form. No part of the manuscript is currently under consideration for publication elsewhere.

Sincerely yours,



Michael V. Johnston, MD